No Data
No Data
No Data
No Data
No Data
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
Revive Therapeutics (RVV.CN), a specialty life sciences company, on Thursday announced that the U.S. Food and Drug Administration has assigned it a meeting date of June 7. Revive had requested a meeti
MT NewswiresApr 18 07:57 ET
Express News | Revive Therapeutics Ltd - Meeting Date Assigned by FDA Is June 7, 2024
Moomoo 24/7Apr 18 07:02 ET
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
GlobeNewswireMar 27 09:08 ET
Revive Therapeutics To Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID
TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of
GlobeNewswireMar 19 07:00 ET
Revive Therapeutics Provides Corporate Update
Yahoo FinanceMar 12 07:00 ET
Mind Medicine Sends Psychedelic Stocks Higher After FDA Status for LSD Formulation
Seeking AlphaMar 7 11:29 ET
No Data
No Data